MarketCapExport financials
Maravai LifeSciences Holdings (MRVI)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Maravai LifeSciences Holdings Cash Flow 2025-2011 | MRVI
Brief overview of Maravai LifeSciences Holdings's cash generation
The review uses the five latest available annual reports between 2021 and 2025.
The latest year produced an operating outflow of -$57.6 million. A return to positive cash generation is important.
Operating cash flow was positive in 4 of five periods. Cash generation worked overall but was not fully stable.
Operating cash flow to net income stands at 3.79x. Accounting results have solid cash support.
Operating cash margin decreased to -31% from 46.1% initially. The quality of receipts deteriorated.
Overall assessment
Maravai LifeSciences Holdings does not yet show sustainable internal cash generation. Stronger OCF and a return to free cash flow are needed.
Annual Cash Flow Maravai LifeSciences Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-57.6 M | 7.46 M | 126 M | 536 M | 369 M | 152 M | 24.1 M | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
23.6 M | 20.9 M | 12.9 M | 7.57 M | 6.41 M | 5.59 M | 3.81 M | - | - | - | - | - | - | - | - |
Accounts Payables |
2.91 M | 12 M | - | 5.99 M | 8.15 M | 8.17 M | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
25.5 M | 38.5 M | 54.6 M | 139 M | 118 M | 51 M | - | - | - | - | - | - | - | - | - |
Total Inventories |
40.5 M | 50.1 M | 51.4 M | 43.2 M | 51.6 M | 33.3 M | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow Maravai LifeSciences Holdings
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | 3.99 M | 8.66 M | -22.8 M | -15.2 M | -10.3 M | -9.39 M | -14.6 M | 13.1 M | 17.4 M | -8.47 M | 7.79 M | 14.2 M | 19.2 M | 85.1 M | 99.3 M | 110 M | 164 M | 162 M | 58.7 M | 106 M | 166 M | 38.3 M | - | 72.8 M | 21.3 M | 9.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
5.74 M | 5.31 M | 6.47 M | 6.51 M | 5.98 M | 5.96 M | 7.03 M | 6.9 M | 5.04 M | 5.56 M | 6.87 M | 6.87 M | 4.07 M | 2.82 M | 6.76 M | 6.24 M | 1.86 M | 1.89 M | 5.53 M | 3.65 M | 1.8 M | 1.62 M | 5.04 M | - | 1.63 M | 1.43 M | 1.69 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
6.48 M | 7.12 M | 8.54 M | 2.91 M | 8 M | 11.5 M | 9.52 M | 12 M | - | - | - | - | - | - | 4.78 M | 5.99 M | 9.46 M | 23.3 M | 10.4 M | 8.15 M | 8.92 M | 11.7 M | 9.81 M | 8.17 M | 8.17 M | 8.17 M | 8.17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
25.7 M | 31.1 M | 33.4 M | 25.5 M | 22.5 M | 27.9 M | 28.5 M | 38.5 M | 28.8 M | 34.7 M | 36.7 M | 54.6 M | 45.7 M | 49 M | 56.3 M | 139 M | 114 M | 120 M | 120 M | 118 M | 65.9 M | 83.5 M | 122 M | 51 M | 51 M | 51 M | 51 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
43.2 M | 41.2 M | 40.5 M | 40.5 M | 45.3 M | 46.7 M | 49.8 M | 50.1 M | 50.5 M | 49.3 M | 49.8 M | 51.4 M | 49.1 M | 47.4 M | 54.8 M | 43.2 M | 62.4 M | 60.1 M | 51.4 M | 51.6 M | 56.2 M | 47.8 M | 47.1 M | 33.3 M | 33.3 M | 33.3 M | 33.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Maravai LifeSciences Holdings, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Biotechnology sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Liminal BioSciences
LMNL
|
- | - | $ 256 M |  Canada |
 |
argenx SE
ARGX
|
$ 928.5 | 3.77 % | $ 56.9 B |  Niderland |
 |
XBiotech
XBIT
|
$ 1.88 | 0.53 % | $ 57.3 M |  USA |
 |
Xencor
XNCR
|
$ 36.19 | 6.28 % | $ 2.69 B | USA |
 |
Xenetic Biosciences
XBIO
|
$ 1.87 | 0.31 % | $ 3.18 M | USA |
 |
Exicure
XCUR
|
$ 0.91 | 2.77 % | $ 5.73 M | USA |
 |
Zealand Pharma A/S
ZEAL
|
- | 0.52 % | $ 821 M |  Danmark |
 |
Xenon Pharmaceuticals
XENE
|
$ 39.02 | 3.56 % | $ 3.09 B | Canada |
 |
Leap Therapeutics
LPTX
|
- | 368.57 % | $ 41.9 M | USA |
 |
Zymeworks
ZYME
|
$ 29.63 | 3.1 % | $ 1.53 B | Canada |
 |
Adial Pharmaceuticals
ADIL
|
$ 3.15 | -35.42 % | $ 2.11 M | USA |
 |
ADMA Biologics
ADMA
|
$ 12.73 | -3.67 % | $ 3.03 B | USA |
 |
Cortexyme
CRTX
|
- | -1.05 % | $ 67.1 M | USA |
 |
Burford Capital Limited
BUR
|
$ 3.6 | -9.22 % | $ 789 M |  Britain |
 |
Daré Bioscience
DARE
|
$ 0.64 | 2.96 % | $ 7.15 M | USA |
 |
Fate Therapeutics
FATE
|
$ 1.84 | -0.54 % | $ 219 M | USA |
 |
Greenwich LifeSciences
GLSI
|
$ 15.15 | 3.41 % | $ 205 M | USA |
 |
Halozyme Therapeutics
HALO
|
$ 103.85 | -15.54 % | $ 12.4 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
$ 15.16 | 6.76 % | $ 13 B |  China |
 |
Aptorum Group Limited
APM
|
- | - | $ 5.72 M | China |
 |
iBio
IBIO
|
$ 0.74 | 0.77 % | $ 77 M | USA |
 |
Kodiak Sciences
KOD
|
$ 99.33 | 9.13 % | $ 5.29 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
$ 0.05 | -14.81 % | $ 547 | USA |
 |
FSD Pharma
HUGE
|
- | 5743.5 % | $ 69.7 M | Canada |
 |
BioAtla
BCAB
|
$ 1.74 | 0.64 % | $ 102 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
- | - | $ 3.85 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
$ 24.77 | -3.73 % | $ 1.19 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
$ 13.47 | 4.1 % | $ 1.2 B | USA |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Canada |
 |
ADiTx Therapeutics
ADTX
|
- | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | USA |